Details of the Drug Pharmacogenomic Perturbation Atlas

Mebendazole Drug Info

Bantenol; Banworm; Besantin; Lomper; MBDZ; Madicure; Mebendan; Mebendazol; Mebendazolum; Mebenoazole; Mebenvet; Mebex; Mebutar; Noverme; Ovitelmin; Pantelmin; Sqworm; Sufil; Surfont; Telmin; Vermicidin; Vermicol; Vermidil; Vermin; Vermirax; Vermox; Verpanyl; Versid; Wormkuur; Abello Farmacia Brand of Mebendazole; Anti Worm; Ardeypharm Brand of Mebendazole; Boots Brand of Mebendazole; Boots Threadworm Treatment; Diba Brand of Mebendazole; Elfar Brand of Mebendazole; Equivurm Plus; Esteve Brand of Mebendazole; Healthypharm Brand of Mebendazole; Janssen Brand of Mebendazole; Leidapharm Brand of Mebendazole; Norgine Brand of Mebendazole; Pfizer Brand of Mebendazole; Pripsen Mebendazole; SSL Brand of Mebendazole; Streger Brand of Mebendazole; Taxandria Brand of Mebendazole; Tedec Meiji Brand of Mebendazole; R 17635; R17635; Anti-Worm; Antiox (TN); Degort's Brand of Mebendazole; Mebendazol [INN-Spanish]; Mebendazole(USAN); Mebendazolum [INN-Latin]; Ovex (TN); Pripsen (TN); R 17,635; R-17635; Vermox (TN); MEBENDAZOLE, 99%; Mebendazole (JAN/USP); Mebendazole (JAN/USP/INN); Mebendazole [USAN:INN:BAN:JAN]; Methyl5-benzoyl benzimidazole-2-carbamate; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester

Therapeutic Class

Antinematodal Agents

Cross-matching ID

PubChem CID

4030

ChEBI ID

CHEMBL685

CAS Number

CAS 31431-39-7

TTD Drug ID

D0J1MI

VARIDT Drug ID

DR00633

INTEDE Drug ID

DR1005

ACDINA Drug ID

D00385

General Information of Drug (ID: DMO14SG)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ribosome biogenesis in eukaryotes	2.03	0.00e+0	52/108 (48.15%)	NOP56;LSG1;PWP2;...
Hypertrophic cardiomyopathy	2.01	0.00e+0	81/90 (90%)	ITGA6;ITGA3;TPM4;...
Dilated cardiomyopathy	1.96	0.00e+0	86/96 (89.58%)	ITGA6;ITGA3;TPM4;...
Colorectal cancer	1.93	0.00e+0	84/86 (97.67%)	EREG;TGFA;GADD45A;...
MAPK signaling pathway	1.81	2.25e-2	272/294 (92.52%)	EREG;FLNA;TGFA;...
Chagas disease	1.81	1.88e-2	93/102 (91.18%)	GNA11;IRAK1;TGFB1;...
Focal adhesion	1.80	1.79e-2	180/201 (89.55%)	CAV1;ACTN1;ITGA6;...
IL-17 signaling pathway	1.80	1.72e-2	84/94 (89.36%)	FOSL1;JUN;CXCL1;...
Proteasome	1.79	1.67e-2	44/46 (95.65%)	ADRM1;PSMD2;PSMD9;...
Mineral absorption	1.78	1.88e-2	48/60 (80%)	MT1E;MT1H;MT1HL1;...
ErbB signaling pathway	1.76	2.28e-2	79/85 (92.94%)	EREG;TGFA;JUN;...
RNA transport	1.73	2.92e-2	128/186 (68.82%)	EIF3B;KPNB1;EEF1A2;...
Hippo signaling pathway	1.71	3.76e-2	120/186 (64.52%)	TGFB1;AXIN1;DVL1;...
Chronic myeloid leukemia	1.68	4.29e-2	72/76 (94.74%)	GADD45A;TGFB1;AKT1;...
Proteoglycans in cancer	1.67	4.09e-2	172/205 (83.9%)	CAV1;FLNA;TGFB1;...
Acute myeloid leukemia	1.67	3.84e-2	66/67 (98.51%)	AKT1;CCND1;NFKB1;...
NF-kappa B signaling pathway	1.66	4.35e-2	90/104 (86.54%)	IRAK1;GADD45A;RELB;...
beta-Alanine metabolism	-1.56	4.95e-2	25/30 (83.33%)	HIBCH;ABAT;ALDH9A1;...
Mismatch repair	-1.57	4.88e-2	22/23 (95.65%)	POLD4;MSH3;MSH2;...
Other glycan degradation	-1.58	4.44e-2	13/18 (72.22%)	HEXB;MAN2B1;HEXA;...
Protein digestion and absorption	-1.62	2.98e-2	78/103 (75.73%)	CPB2;ATP1B3;ELN;...
Sulfur metabolism	-1.62	3.02e-2	9/10 (90%)	TST;PAPSS1;SUOX;...
Tyrosine metabolism	-1.66	2.12e-2	30/36 (83.33%)	ALDH3B1;GSTZ1;TPO;...
Citrate cycle (TCA cycle)	-1.68	1.73e-2	30/30 (100%)	SUCLG2;DLD;ACO1;...
Peroxisome	-1.70	1.41e-2	72/82 (87.8%)	ACOT8;PXMP4;PMVK;...
Tryptophan metabolism	-1.74	1.18e-2	35/42 (83.33%)	ALDH8A1;DLD;ACAT2;...
Arachidonic acid metabolism	-1.81	7.92e-3	48/61 (78.69%)	ALOX5;GGT1;PLA2G12A;...
DNA replication	-1.83	4.97e-3	34/36 (94.44%)	RFC5;FEN1;RFC4;...
Pentose and glucuronate interconversions	-1.87	3.73e-3	17/34 (50%)	UGT2B17;UGT2B28;UGT2A3;...
Ascorbate and aldarate metabolism	-1.92	1.72e-3	15/30 (50%)	UGT2B17;UGT2B28;UGT2A3;...
Propanoate metabolism	-1.93	1.86e-3	30/34 (88.24%)	PCCB;SUCLG2;BCKDHA;...
Glycolysis / Gluconeogenesis	-1.94	2.03e-3	56/67 (83.58%)	TPI1;DLD;ALDOB;...
Primary bile acid biosynthesis	-1.94	2.24e-3	15/17 (88.24%)	CYP7B1;AKR1D1;BAAT;...
Valine, leucine and isoleucine degradation	-1.99	8.28e-4	42/48 (87.5%)	MCCC1;BCKDHA;DLD;...
Fatty acid degradation	-2.01	0.00e+0	40/43 (93.02%)	ACAT2;ADH1A;ACADM;...
Drug metabolism	-2.04	0.00e+0	78/151 (51.66%)	FMO3;UGT2B17;ADH1A;...
Glyoxylate and dicarboxylate metabolism	-2.05	0.00e+0	23/30 (76.67%)	PCCB;SHMT1;DLD;...
Pyruvate metabolism	-2.12	0.00e+0	41/47 (87.23%)	DLD;HAGH;GRHPR;...
Oxidative phosphorylation	-2.13	0.00e+0	93/133 (69.92%)	COX11;NDUFA8;ATP12A;...
Steroid hormone biosynthesis	-2.15	0.00e+0	43/61 (70.49%)	CYP7B1;AKR1D1;SULT2B1;...
Glutathione metabolism	-2.22	0.00e+0	43/57 (75.44%)	PRDX6;GSTK1;MGST2;...
Metabolism of xenobiotics by cytochrome P450	-2.50	0.00e+0	49/77 (63.64%)	GSTP1;AKR7A3;CYP3A4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 40uM	6H, 24H, 48H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	12uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H